VibroSense Dynamics (VSD) Q1 25/26 earnings summary

Executive summary

• Net sales for Q1 2026 were SEK 317,880, down from SEK 753,596 year-over-year, mainly due to the loss of a major customer in 2025.

• Loss after financial items improved to SEK -989,586 from SEK -1,232,330 year-over-year.

• Strong interest from clinics and researchers in Europe; expansion efforts ongoing in Asia, with new distributor agreements in Turkey.

• Clinical studies in diabetes and oncology continue to strengthen the evidence base for the technology.

Financial highlights

• Net sales for Q1 2026: SEK 317,880 (Q1 2025: SEK 753,596).

• Net loss after financial items: SEK -989,586 (Q1 2025: SEK -1,232,330).

• Earnings per share: SEK -0.03 (Q1 2025: SEK -0.05).

• Cash and cash equivalents at March 31, 2026: SEK 5,751,147 (March 31, 2025: SEK 8,833,263).

• Cash flow for the quarter: SEK -994,396 (Q1 2025: SEK -1,442,047).

Outlook and guidance

• Positive outlook for the remainder of 2026, with expectations of new distributor partnerships before summer.

• Continued focus on international expansion and strengthening clinical collaborations in key markets.